Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295467 | 1.00 | EPHX1 (0.46) | EPHX1HSD17B10USP2CYP3A4CYP2C9 | |
| SCHEMBL2299966 | 0.87 | ALOX15 (0.53) | EPHX1HSD17B10ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2297714 | 0.87 | ALOX15 (0.53) | EPHX1HSD17B10ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2293896 | 0.87 | MGLL (0.47) | CYP1A2FAAHCYP2D6RAB9A | |
| SCHEMBL2298749 | 0.87 | MGLL (0.47) | CYP1A2FAAHCYP2D6RAB9A | |
| SCHEMBL2296614 | 0.85 | CYP1A2 (0.44) | CYP3A4CYP2C9ALDH1A1CYP1A2TSHR | |
| SCHEMBL2294195 | 0.85 | CYP1A2 (0.44) | CYP3A4CYP2C9ALDH1A1CYP1A2TSHR | |
| SCHEMBL3369775 | 0.84 | SCD5 (0.44) | KMT2AUSP30NPC1MEN1SCD5 | |
| SCHEMBL4598876 | 0.84 | SCD5 (0.44) | KMT2AUSP30NPC1MEN1SCD5 | |
| SCHEMBL3375799 | 0.84 | SCD5 (0.44) | KMT2AUSP30NPC1MEN1SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | claimed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| CN-102120741-A | Production method of an optically active compound | MITSUBISHI TANABE PHARMA CORP | 2011-07-13 | — | — | CN | disclosed |
| CN-102050820-A | Preparation method of compound with optical activity | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | EPHX1 3754/4885HSD17B10 1902/4885USP2 3825/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | EPHX1 3754/4885HSD17B10 1902/4885USP2 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.